Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10201/36009
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Díaz-Gil, Juan J. | es |
dc.contributor.author | García-Monzón, Carmelo | es |
dc.contributor.author | Rúa, Carmen | - |
dc.contributor.author | Martín Sanz, Paloma | - |
dc.contributor.author | Cereceda, Rosa M. | - |
dc.contributor.author | Miquilena-Colina, María E. | - |
dc.contributor.author | Machín, Celia | - |
dc.contributor.author | Fernández Martínez, Amalia | - |
dc.contributor.author | García Cañero, Rafael | - |
dc.date.accessioned | 2013-09-24T11:34:30Z | - |
dc.date.available | 2013-09-24T11:34:30Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0213-3911 | es |
dc.identifier.uri | http://hdl.handle.net/10201/36009 | - |
dc.description.abstract | The antifibrotic activity of Liver Growth Factor (LGF), a liver mitogen, was previously demonstrated in several models of rat liver fibrosis and even in extrahepatic sites, such as carotid artery in hypertensive rats and rat CdCl2-induced lung fibrosis. In the present study, we have attempted to examine in depth its mechanism of antifibrotic action in bile duct-ligated (BDL) rats, with special emphasis on its activity in fibrogenic liver cells. BDL rats received either LGF 9 μg/week for 2 or 3 weeks (BDL+LGF, n=20/group) or saline (BDL+S, n=20/group), at times 0, week 2, or week 5 after operation. Groups were compared in terms of liver a- smooth muscle actin (SMA) content (western blotting and immunohistochemistry), hepatic apoptosis, liver desmin content (western blotting), and serum endothelin-1 (ELISA). LGF produced a marked decrease in liver a-SMA content compared with saline-injected rats, especially evident at longer times (5w and 8w; p<0.05), accompanied by a decrease in hepatic a-SMA+ cells. This decrease was not due to the killing of activated hepatic stellate cells (HSC) or myofibroblasts by LGF, since there was a slight decrease in hepatic apoptosis that was more evident at 2w (p<0.05). Moreover, LGF did not seem to influence HSC proliferation, as shown by measuring liver desmin content. The antifibrotic activity exerted by LGF seems to be closely related to a modulation of the activation state of fibrogenic liver cells (activated HSC and myofibroblasts) in BDL rats. | es |
dc.format | application/pdf | es |
dc.format.extent | 7 | es |
dc.language | eng | es |
dc.publisher | Murcia : F. Hernández | es |
dc.relation.ispartof | Histology and histopathology | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.subject | Fibrosis | es |
dc.subject | Myofibroblasts | es |
dc.subject.other | 576 - Biología celular y subcelular. Citología | es |
dc.title | Liver growth factor antifibrotic activity in vivo is associated with a decrease in activation of hepatic stellate cells | es |
dc.type | info:eu-repo/semantics/article | es |
Aparece en las colecciones: | Vol.24, nº4 (2009) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Liver growth factor antifibrotic activity in vivo is associated with a.pdf | 1,47 MB | Adobe PDF | Visualizar/Abrir |
Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.